Market Overview

Morning Market Losers

Related FNSR
Oclaro Down On FQ1 Outlook; Sector Falls After Hours
Barrington Initiates Coverage On Finisar, Sees Growth Drivers
Related OMED
OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer
OncoMed's OMP-54F28 on Partial Clinical Hold - Analyst Blog

Finisar (NASDAQ: FNSR) shares tumbled 23.56% to $19.30 after the company reported downbeat earnings for the fourth quarter and issued a weak profit forecast for the current quarter.

OncoMed Pharmaceuticals (NASDAQ: OMED) dropped 20.64% to $19.76 after the company voluntarily stopped enrollment for Phase 1 Vantictumab.

Cesca Therapeutics (NASDAQ: KOOL) declined 16.39% to $1.48 after the company priced priced 7.53 million share offering at $1.55 per share.

Oculus Innovative Sciences (NASDAQ: OCLS) fell 7.29% to $3.05 on Q4 results. The company's net income rose $9.9 million to $7.5 million in the quarter.

TG Therapeutics (NASDAQ: TGTX) shares declined 7.26% to $8.18 after the company's TG-1101 in combination with Ibrutinib showed a 90% response rate in patients with previously treated CLL and MCL.

Achillion Pharmaceuticals (NASDAQ: ACHN) dropped 4.10% to $6.55 after dropping 6.32% on Thursday.

Posted-In: market losersNews Movers & Shakers Intraday Update Markets

 

Related Articles (ACHN + FNSR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters